Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Summit Therapeutics Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:06.681 A warm welcome to Sandvik's presentation of the third quarter results 2025. 00:00:06.685 -- 00:00:11.414 My name is Louise Cheddar, Head of Investor Relations here at Sandvik and beside me I 00:00:11.414 -- 00:00:16.602 have our CEO Stefan Widing and CFO Cecilia Felton. 00:00:16.602 -- 00:00:21.053 We will do as we usually do. We will start with the presentation. 00:00:21.053 -- 00:00:26.226 Stefan and Cecilia will take you through the highlights of the quarter. 00:00:26.226 -- 00:00:30.115 And then we will move on to your questions. 00:00:30.115 -- 00:00:33.042 And with this, it's time to listen to the presentation. 00:00:33.042 -- 00:00:34.726 And over to you, Stefan. 00:00:34.726 -- 00:00:39.174 Thank you, Louise. And also from my side, welcome to Sandvik's third quarter report in 00:00:39.174 -- 00:00:44.364 2025. It's a quarter that's been characterized by a strong 00:00:44.364 -- 00:00:49.072 momentum and strong demand in several of our key segments. 00:00:49.072 -- 00:00:54.121 We see a strong demand in mining, in software solutions, Also, cutting tools are 00:00:54.121 -- 00:00:59.750 up by single digits, and the underlying demand in general engineering has been stable. 00:00:59.750 -- 00:01:04.818 We have seen strong growth also in aerospace and defense and, however, a 00:01:04.818 -- 00:01:08.363 weak picture in automotive. 00:01:08.363 -- 00:01:12.750 In infrastructure, the demand has been mixed, and I'll come back to that later in the 00:01:12.750 -- 00:01:18.026 presentation. Total order intake grew by 7% and organically we grew 00:01:18.026 -- 00:01:23.043 by 16%. Total revenues decreased by 4% 00:01:23.043 -- 00:01:26.568 but grew organically by 5%. 00:01:27.123 -- 00:01:32.147 We see resilient delivery on the margin...